Comprehensive analysis of Seriphidium kurramense: GC/MS profiling, antibacterial and antibiofilm activities, molecular docking study and in-silico ADME profiling

Abstract

AbstractThe emergence of drug-resistant bacteria poses a substantial threat to global healthcare, necessitating the development of novel therapeutic approaches. Seriphidium kurramense, a well-known aromatic, medicinal, and culinary herb, has garnered attention due to its potential medicinal properties. In this study, we investigated the chemical composition, antibacterial, and antibiofilm activities of Seriphidium kurramense plant extract. The coupled analysis of GC/MS (Gas chromatography/ mass spectrometry) has identified seventeen components in the extract, with major constituents including α-santonin (42.2%), eucalyptol (3.04%), and bicyclo[3.1.0]hexan-3-one (10.1%). The research encompassed four bacterial strains (E. coli, Bacillus, Staphylococcus aureus, and Salmonella), all involved in biofilm formation. The results indicated that the plant extract exhibited varying efficacy against the tested bacterial strains. Additionally, the ADME profiling of the identified phytocompounds supported their potential as drug candidates with promising pharmacokinetic properties. In-silico molecular docking studies revealed that among the 17 identified phytocompounds, lumisantonin displayed the highest effectiveness as an antibiofilm and antibacterial agent. It was closely followed by n-Hexadecanoic acid, ß-Copaene, and other compounds examined in the docking studies. These compounds exhibited high binding scores with target proteins, suggesting their potential as therapeutic agents. This comprehensive investigation not only sheds light on the chemical composition and pharmacological properties of Seriphidium kurramense compound but also presents a promising avenue for developing innovative drugs against drug-resistant bacterial strains. The results of this investigation provide valuable insights to the ongoing efforts in addressing the pressing issue of drug-resistant bacteria in global healthcare.